Institute of Epidemiology, Kiel University, University Hospital Schleswig-Holstein, Kiel, Germany.
Institute of Experimental Medicine, Division of Biomedical Ethics, Kiel University, University Hospital Schleswig-Holstein, Kiel, Germany.
Eur J Hum Genet. 2019 Jun;27(6):841-847. doi: 10.1038/s41431-019-0340-6. Epub 2019 Jan 25.
The research exemption implemented in the new EU General Data Protection Regulation (EU-GDPR) gives member states leeway in determining whether patient consent is required for secondary data use in medical research. However, even though broad consent has become common in data-rich medical research in many EU countries, giving up consent altogether is likely to be controversial. The aim of this study was to examine whether abolishing consent for secondary data use would be acceptable to patients. A questionnaire study was conducted among 700 outpatients of a northern German university hospital to assess their attitude towards use of clinical data for scientific research without consent. There was both strong willingness to give broad consent for secondary data use (468 of 503 responders, 93.0%) and strong approval of abolishing patient consent (n = 381, 75.7%) among study participants. The willingness to give consent was moderately associated with approval of the respective stipulations by the EU-GDPR. In research settings where broad consent is widely accepted (e.g. university hospitals), abolishing consent for secondary research use of clinical data will likely be acceptable to a large majority of patients.
新的欧盟一般数据保护条例(EU-GDPR)中实施的研究豁免权赋予成员国在确定是否需要患者同意进行医疗研究中的二次数据使用方面的自由裁量权。然而,尽管在许多欧盟国家的数据丰富的医学研究中广泛同意已经变得很常见,但完全放弃同意可能会引起争议。本研究旨在探讨取消二次数据使用的同意是否能被患者接受。在德国北部一所大学医院的 700 名门诊患者中进行了一项问卷调查研究,以评估他们对在没有同意的情况下使用临床数据进行科学研究的态度。研究参与者中既有强烈的意愿(503 名应答者中有 468 名,93.0%)同意二次数据的广泛使用,也有强烈的赞成(n=381,75.7%)取消患者同意。同意的意愿与欧盟 GDPR 对各自规定的批准程度呈中度相关。在广泛接受广泛同意的研究环境中(例如,大学医院),取消对临床数据二次研究使用的同意,可能会被绝大多数患者接受。